Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PLSE Stock Forecast 2026-2027
$25.89
Current Price
$1.79B
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PLSE Price Targets
+23.6%
To High Target of $32.00
+15.9%
To Median Target of $30.00
+15.9%
To Low Target of $30.00
PLSE Price Momentum
-7.6%
1 Week Change
+6.2%
1 Month Change
+61.1%
1 Year Change
+88.6%
Year-to-Date Change
-16.5%
From 52W High of $31.00
+106.1%
From 52W Low of $12.56
📊 TOP ANALYST CALLS
Did PLSE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Pulse Biosciences is one of their latest high-conviction picks.
Latest PLSE Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, PLSE has a bullish consensus with a median price target of $30.00 (ranging from $30.00 to $32.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $25.89, the median forecast implies a 15.9% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from William Plovanic at Canaccord Genuity, projecting a 23.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PLSE Analyst Ratings
3
Buy
0
Hold
0
Sell
PLSE Price Target Range
Low
$30.00
Average
$30.00
High
$32.00
Current: $25.89
Latest PLSE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PLSE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 4, 2026 | Canaccord Genuity | William Plovanic | Buy | Initiates | $32.00 |
| Jul 7, 2025 | Oppenheimer | Outperform | Initiates | $N/A | |
| Sep 21, 2022 | Maxim Group | Hold | Downgrade | $N/A | |
| May 13, 2022 | HC Wainwright & Co. | Neutral | Downgrade | $N/A | |
| Apr 1, 2022 | Stephens & Co. | Overweight | Maintains | $N/A | |
| Apr 1, 2022 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Feb 10, 2022 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 16, 2021 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jul 27, 2021 | Stephens & Co. | Overweight | Initiates | $N/A | |
| Mar 11, 2021 | Maxim Group | Buy | Initiates | $N/A | |
| Jan 26, 2021 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| May 12, 2020 | H.C. Wainwright | Buy | Upgrade | $N/A | |
| May 12, 2020 | HC Wainwright & Co. | Buy | Upgrade | $N/A | |
| Feb 14, 2020 | H.C. Wainwright | Neutral | Downgrade | $N/A | |
| Feb 14, 2020 | HC Wainwright & Co. | Neutral | Downgrade | $N/A | |
| Feb 25, 2019 | H.C. Wainwright | Buy | Initiates | $N/A | |
| Feb 25, 2019 | HC Wainwright & Co. | Buy | Initiates | $N/A |
Pulse Biosciences, Inc. (PLSE) Competitors
The following stocks are similar to Pulse Biosciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
PLSE
Pulse Biosciences
mkt cap
1.82B
Pulse Biosciences, Inc. (PLSE) Financial Data
Pulse Biosciences, Inc. has a market capitalization of $1.79B with a P/E ratio of -24.0x. The company generates $751,000 in trailing twelve-month revenue with a -54.0% profit margin.
Revenue growth is +51.9% quarter-over-quarter, while maintaining an operating margin of -4,775.6% and return on equity of -80.7%.
Valuation Metrics
Market Cap
$1.79B
Enterprise Value
$1.76B
P/E Ratio
-24.0x
PEG Ratio
-3.0x
Price/Sales
2,422.8x
Growth & Margins
Revenue Growth (YoY)
+51.9%
Gross Margin
+7.7%
Operating Margin
-4,775.6%
Net Margin
-54.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+3.8%
Current Ratio
7.3x
Debt/Equity
10.8x
ROE
-80.7%
ROA
-45.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Pulse Biosciences, Inc. (PLSE) Business Model
About Pulse Biosciences, Inc.
What They Do
Develops bioelectric medicine technologies for ablation.
Business Model
The company generates revenue through its innovative nsPFA technology and associated products designed for various medical applications, including dermatology and cardiology. Its flagship products, such as the CellFX System and related devices, provide healthcare professionals with advanced tools for precise tissue ablation, thereby enhancing patient outcomes and procedural efficiency.
Additional Information
Founded in 2014 and based in Miami, Florida, Pulse Biosciences is focused on addressing significant healthcare needs, such as treating atrial fibrillation and benign tumors, through its patented technology. The company is positioned within the growing field of minimally invasive therapies, appealing to investors interested in the medical technology sector.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
116
CEO
Mr. Paul Arthur LaViolette M.B.A.
Country
United States
IPO Year
2016
Website
www.pulsebiosciences.comPulse Biosciences, Inc. (PLSE) Latest News & Analysis
Latest News
Quick Summary
Pulse Biosciences, Inc. (PLSE) presented at the Goldman Sachs 47th Annual Global Healthcare Conference, highlighting its developments and strategies in the healthcare sector.
Why It Matters
Pulse Biosciences' presentation at a major healthcare conference signals potential growth and innovation, attracting investor interest and influencing stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Pulse Biosciences, Inc. plans to redeem its remaining common stock warrants from the July 3, 2024 rights offering around June 10, 2026.
Why It Matters
Pulse Biosciences plans to redeem common stock warrants, potentially affecting share liquidity and investor sentiment, influencing stock price and investment strategies.
Source: Business Wire
Market Sentiment:
Neutral
Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
1 month ago
Quick Summary
Pulse Biosciences (Nasdaq: PLSE) will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10 at 10:00 am ET, with a webcast available for investors.
Why It Matters
Pulse Biosciences' participation in a major healthcare conference may enhance visibility and investor interest, potentially impacting stock performance and market perception.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Pulse Biosciences, Inc (PLSE) is being evaluated for its potential as a top stock pick for momentum investors. Further analysis is needed to determine its suitability.
Why It Matters
The excerpt signals potential interest in Pulse Biosciences for momentum investing, suggesting it may experience increased trading activity and price volatility, impacting investor sentiment and decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Pulse Biosciences, Inc. (PLSE) presented at the Bank of America Global Healthcare Conference, showcasing its developments and future plans in the healthcare sector.
Why It Matters
Pulse Biosciences' presentation at a major healthcare conference can signal potential investor interest, influence stock performance, and provide insights into its strategic direction and innovations.
Source: Seeking Alpha
Market Sentiment:
Neutral
ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million
2 months ago
Quick Summary
Pulse Biosciences' Co-Chairmen, Robert Duggan and CEO Paul LaViolette, bought 675,233 shares through the company's at-the-market equity offering program.
Why It Matters
The purchase of shares by key executives signals confidence in Pulse Biosciences' future, potentially boosting investor sentiment and stock value.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About PLSE Stock
What is Pulse Biosciences, Inc.'s (PLSE) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Pulse Biosciences, Inc. (PLSE) has a median price target of $30.00. The highest price target is $32.00 and the lowest is $30.00.
Is PLSE stock a good investment in 2027?
According to current analyst ratings, PLSE has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $25.89. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PLSE stock?
Wall Street analysts predict PLSE stock could reach $30.00 in the next 12 months. This represents a 15.9% increase from the current price of $25.89. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Pulse Biosciences, Inc.'s business model?
The company generates revenue through its innovative nsPFA technology and associated products designed for various medical applications, including dermatology and cardiology. Its flagship products, such as the CellFX System and related devices, provide healthcare professionals with advanced tools for precise tissue ablation, thereby enhancing patient outcomes and procedural efficiency.
What is the highest forecasted price for PLSE Pulse Biosciences, Inc.?
The highest price target for PLSE is $32.00 from William Plovanic at Canaccord Genuity, which represents a 23.6% increase from the current price of $25.89.
What is the lowest forecasted price for PLSE Pulse Biosciences, Inc.?
The lowest price target for PLSE is $30.00 from at , which represents a 15.9% increase from the current price of $25.89.
What is the overall PLSE consensus from analysts for Pulse Biosciences, Inc.?
The overall analyst consensus for PLSE is bullish. Out of 2 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $30.00.
How accurate are PLSE stock price projections?
Stock price projections, including those for Pulse Biosciences, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2026 3:32 AM UTC